Steven I. Sherman, M.D.

Peer-Reviewed Articles

1. Capdevila,J, Krajewski, J, Hernando, J, Robinson, B, Sherman,S Jarzab, B, Lin, CC, Vaisman, F, Hoff, A, Hitre, E, Bowles, D, Williamson, D, Levytskyy, R, Oliver, J, Keam, B, Brose, M. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid 34(3):347-359, 2024. e-Pub 2024. PMID: 38062732.
2. Taylor MH, Takahashi S, Capdevila J, Tahara M, Leboulleux S, Kiyota N, Dutcus CE, Xie R, Robinson B, Sherman S, Habra MA, Elisei R, Wirth LJ. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio With Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated With Lenvatinib. Thyroid 31(8):1226-1234, 2021. e-Pub 2021. PMID: 33637020.
3. Bagheri-Yarmand R, Dadu R, Ye L, Shiny Jebaraj Y, Martinez JA, Ma J, Tarapore RS, Allen JE, Sherman SI, Williams MD, Gagel RF. ONC201 shows anti-cancer activity against medullary thyroid cancer via transcriptional inhibition of RET, VEGFR2, and IGFBP2. Mol Cancer Ther 20(4):665-675, 2021. e-Pub 2021. PMID: 33536187.
4. Nies M, Vassilopoulou-Sellin R, Bassett RL, Yedururi S, Zafereo ME, Cabanillas ME, Sherman SI, Links TP, Waguespack SG. Distant metastases from childhood differentiated thyroid carcinoma: clinical course and mutational landscape. J Clin Endocrinol Metab 106(4):e1683-e1697, 2021. e-Pub 2020. PMID: 33382403.
5. Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open 5(5):e000799, 2020. e-Pub 2020. PMID: 33097651.
6. Yin N, Sherman SI, Pak Y, Litofsky DR, Gianoukakis AG, National Thyroid Cancer Treatment Cooperative Study Group. The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence. Thyroid 30(10):1490-1495, 2020. e-Pub 2020. PMID: 32228151.
7. Jozaghi Y, Zafereo ME, Perrier ND, Wang JR, Grubbs E, Gross ND, Fisher S, Sturgis EM, Goepfert RP, Lai SY, Best C, Busaidy NL, Cabanillas ME, Dadu R, Gagel RF, Habra MA, Hu MI, Jimenez C, Sherman SI, Thosani S, Varghese J, Waguespack SG, Weitzman S, Ying AK, Graham PH. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck 42(6):1325-1328, 2020. e-Pub 2020. PMID: 32437031.
8. Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS. A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clin Cancer Res 25(18):5475-5484, 2019. e-Pub 2019. PMID: 31186313.
9. Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol 145(8):1977-1986, 2019. e-Pub 2019. PMID: 31309300.
10. Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head Neck 1(6):1928-1934, 2019. e-Pub 2019. PMID: 30758123.
11. Hurst Z, Liyanarachchi S, He H, Brock P, Sipos J, Nabhan F, Kebebew E, Green P, Cote GJ, Sherman S, Walker CJ, Chang YS, Xue S, Hollingsworth B, Li W, Genutis L, Menq E, de la Chapelle A, Jhiang SM. Risk Haplotypes Uniquely Associated with Radioiodine Refractory Thyroid Cancer Patients of High African Ancestry. Thyroid 29(4):530-539, 2019. e-Pub 2019. PMID: 30654714.
12. Bagheri-Yarmand R, Sinha KM, Li L, Lu Y, Cote GJ, Sherman SI, Gagel RF. Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer. Mol Cancer Res 17(3):751-760, 2019. e-Pub 2018. PMID: 30552230.
13. Jaber T, Waguespack SG, Cabanillas ME, Elbanan M, Vu T, Dadu R, Sherman SI, Amit M, Santos EB, Zafereo M, Busaidy NL. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine. J Clin Endocrinol Metab 103(10):3698-3705, 2018. e-Pub 2018. PMID: 30032208.
14. Tam S, Boonsripitayanon M, Amit M, Fellman BM, Li Y, Busaidy N, Cabanillas M, Dadu R, Sherman SI, Waguespack SG, Williams MD, Goepfert RP, Gross ND, Perrier N, Sturgis E, Zafereo M.. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging 7th and 8th editions. Thyroid(10):1301-1310, 2018. e-Pub 2018. PMID: 30141373.
15. Subbiah V, Sen S, Hess K, Janku F, Hong DS, Khatua S, Karp D, Munoz J, Falchook GS, Groisberg R, Tsimberidou AM, Sherman SI, Hwu P, Meric-Bernstam F. Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. JCO Precision Oncology, 2018. e-Pub 2018. PMID: 32913986.
16. Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer 124(11):2365-2372, 2018. e-Pub 2018. PMID: 29656442.
17. Romero Arenas MA, Rich TA, Hyde SM, Busaidy NL, Cote GJ, Hu MI, Gagel RF, Gidley PW, Jimenez C, Kupferman ME, Peterson SK, Sherman SI, Ying A, Bassett RL, Waguespack SG, Perrier ND, Grubbs EG. Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol 25(5):1395-1402, 2018. e-Pub 2018. PMID: 29427212.
18. Giordano TJ, Haugen BR, Sherman SI, Shah MH, Caoili EM, Koenig RJ. Pioglitazone Therapy of PAX8-PPARy Fusion Protein Thyroid Carcinoma. J Clin Endocrinol Metab 103(4):1277-1281, 2018. e-Pub 2018. PMID: 29373711.
19. Sherman SI, Kloos RT, Tuttle RM, Pontecorvi A, Völzke H, Harper K, Vance C, Alston JT, Usborne AL, Sloop KW, Lakshmanan M. No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer. Diabet Med 35(3):381-385, 2018. e-Pub 2017. PMID: 28755389.
20. Hegedüs L, Sherman SI, Tuttle RM, von Scholten BJ, Rasmussen S, Karsbøl JD, Daniels GH, LEADER Publication Committee on behalf of the LEADER Trial Investigators. No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. Diabetes Care 41(3):620-622, 2018. e-Pub 2017. PMID: 29279300.
21. Schlumberger M, Elisei R, Müller S, Schöffski P, Brose M, Shah M, Licitra L, Krajewska J, Kreissl MC, Niederle B, Cohen EEW, Wirth L, Ali H, Clary DO, Yaron Y, Mangeshkar M, Ball D, Nelkin B, Sherman S. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol 28(11):2813-2819, 2017. PMID: 29045520.
22. Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients with Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 102(9):3591-3599, 2017. e-Pub 2017. PMID: 28911154.
23. Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT Trial and their association with survival outcomes. Endocrine 56(1):121-128, 2017. e-Pub 2017. PMID: 28155175.
24. Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Paschke R, Dutcus CE, Hihara T, McGrath S, Matijevic M, Kadowaki T, Funahashi Y, Sherman SI. Exploratory Analysis of Biomarkers Associated with Clinical Outcomes from the Study of Lenvatinib in Differentiated Cancer of the Thyroid. Eur J Cancer 75:213-221, 2017. e-Pub 2017. PMID: 28237867.
25. Tang C, Sherman SI, Price M, Weng J, Davis SE, Hong DS, Yao JC, Buzdar A, Wilding G, Lee JJ. Clinical trial characteristics and barriers to participant accrual: The MD Anderson cancer center experience over 30 years, a historical foundation for trial improvement. Clin Cancer Res 23(6):1414-1421, 2017. e-Pub 2017. PMID: 28275168.
26. Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EE, Schöffski P, Wirth LJ, Mangeshkar M, Aftab DT, Brose MS. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer 122(24):3856-3862, 2016. PMID: 27525386.
27. Xu JY, Murphy WA, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 101(12):4871-4877, 2016. e-Pub 2016. PMID: 27662441.
28. Xu JY, Grubbs EG, Waguespack SG, Jimenez C, Gagel RF, Sosa JA, Sellin RV, Dadu R, Hu MI, Trotter CS, Jackson M, Rich TA, Hyde SM, Sherman SI, Cote GJ. Medullary Thyroid Carcinoma Associated with Germline RET(K666N) Mutation. Thyroid 26(12):1744-1751, 2016. e-Pub 2016. PMID: 27673361.
29. Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, Taylor MH, Kim SB, Krzyzanowska MK, Capdevila J, Sherman SI, Tahara M. Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. J Clin Endocrinol Metab 101(11):4103-4109, 2016. e-Pub 2016. PMID: 27548104.
30. Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA, Cote GJ, Sherman SI. Detection and Prognostic Significance of Circulating Tumor Cells in Patients with Metastatic Thyroid Cancer. J Clin Endocrinol Metab 101(11):4461-4467, 2016. e-Pub 2016. PMID: 27575943.
31. Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 17(9):1272-1282, 2016. e-Pub 2016. PMID: 27460442.
32. Falchook GS, Rady P, Konopinski JC, Busaidy N, Hess K, Hymes S, Nguyen HP, Prieto VG, Bustinza-Linares E, Lin Q, Parkhurst KL, Hong DS, Sherman S, Tyring SK, Kurzrock R,. Merkel Cell Polyomavirus and Human Papilloma Virus in Proliferative Skin Lesions Arising in Patients Treated with BRAF Inhibitors Archives of Dermatological Research. Archives of Dermatological Research 308(5):357-365, 2016. e-Pub 2016. PMID: 27098388.
33. Evers C, Duose DY, Mehrotra M, Hai T, Houston MR, Hu PC, Luthra R, Sherman SI, Cote CJ. Liquid Biopsy: Comparison of Mutation Detection Methods for Measurement of RET M918T Circulating Cell-Free DNA in Medullary Thyroid Cancer Patients. Cancer Genetics 209(6):287, 2016.
34. Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Canc Res 22(1):44-53, 2016. e-Pub 2015. PMID: 26311725.
35. Haugen BR, Alexander EK, Bible KC, Doherty G, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1):1-133, 2016. e-Pub 2015. PMID: 26462967.
36. Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, Lipson D, Ross JS, Miller VA, Shah MH, Ali SM, Stephens PJ. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology 90(6):339-46, 2016. e-Pub 2016. PMID: 27207748.
37. Kiyota N, Schlumberger M, Muro K, Ando Y, Takahashi S, Yasukazu K, Wirth L, Robinson B, Sherman S, Suzuki T, Fujino K, Gupta A, Hayato S, Tahara M. Subgroup analysis of Japanese patients in a phase 3 study of Lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Science Journal 106(12):1714-21, 2015. e-Pub 2015. PMID: 26426092.
38. Dadu R, Hu MI, Cleeland C, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying A, Fox P, Cabanillas ME. Efficacy of the natural clay, calcium aluminosilicate anti-diarrheal, in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life: A pilot study. Thyroid 25(10):1085-90, 2015. e-Pub 2015. PMID: 26200040.
39. McLeod DS, Jonklaas J, Brierley JD, Ain KB, Cooper DS, Fein HG, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Xing M, Litofsky DR, Maxon HR, Sherman SI. Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis. Thyroid 25(10):1097-1105, 2015. e-Pub 2015. PMID: 26203804.
40. Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, Ladenson PW, Ain KB, Fein HG, Haugen BR, Magner J, Skarulis MC, Steward DL, Xing M, Maxon HR, Sherman SI. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012. J Clin Endocrinol Metab 100(9):3270-3279, 2015. e-Pub 2015. PMID: 26171797.
41. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer 121(16):2749-56, 2015. e-Pub 2015. PMID: 25913680.
42. Carhill AA, Litofsky DR, Sherman SI. Unique characteristics and outcomes of patients diagnosed with both primary thyroid and primary renal cell carcinoma. Endocr Pract 21(5):461-7, 2015. e-Pub 2014. PMID: 25536972.
43. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7):621-630, 2015. PMID: 25671254.
44. Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 25(1):71-7, 2015. e-Pub 2014. PMID: 25285888.
45. Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab 100(1):E77-81, 2015. PMID: 25353071.
46. Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw 12(12):1671-80, 2014. PMID: 25505208.
47. Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid 24(10):1508-14, 2014. e-Pub 2014. PMID: 25102375.
48. Cancer Genome Atlas Research Network (Sherman SI group member). Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3):676-90, 2014. PMID: 25417114.
49. Rich TA, Feng L, Busaidy N, Cote GJ, Gagel RF, Hu M, Jimenez C, Lee JE, Perrier N, Sherman SI, Waguespack SG, Ying A, Grubbs E. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid 24(7):1096-1106, 2014. e-Pub 2014. PMID: 24617864.
50. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ, DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384(9940):319-28, 2014. e-Pub 2014. PMID: 24768112.
51. Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 99(6):2086-94, 2014. e-Pub 2014. PMID: 24628550.
52. Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist 19(5):477-82, 2014. e-Pub 2014. PMID: 24733667.
53. McLeod DS, Cooper DS, Ladenson PW, Ain KB, Brierley JD, Fein HG, Haugen BR, Jonklaas J, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI For The National Thyroid Cancer Treatment Cooperative Study Group. Prognosis of differentiated thyroid cancer in relation to serum TSH and thyroglobulin antibody status at time of diagnosis. Thyroid 24(1):35-42, 2014. e-Pub 2013. PMID: 23731273.
54. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring V600E BRAF mutation. Thyroid 23(10):1277-83, 2013. e-Pub 2013. PMID: 23489023.
55. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31(29):3639-46, 2013. e-Pub 2013. PMID: 24002501.
56. Kurzrock R, Wheler AJ, Fu S, Naing A, Busaidy N, Hong D, Sherman S. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol 24(9):2256-61, 2013. e-Pub 2013. PMID: 23676418.
57. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 98(1):31-42, 2013. e-Pub 2012. PMID: 23185034.
58. Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI, National Thyroid Cancer Treatment Cooperative Study Group. The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab 97(6):E878-87, 2012. e-Pub 2012. PMID: 22496497.
59. Moreno MA, Edeiken-Monroe BS, Siegel ER, Sherman SI, Clayman GL. In papillary thyroid cancer, preoperative central neck Ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. Thyroid 22(4):347-55, 2012. e-Pub 2012. PMID: 22280230.
60. Clayman GL, Agarwal G, Edeiken BS, Waguespack SG, Roberts DB, Sherman SI. Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma. Thyroid 21(12):1309-16, 2011. PMID: 22136266.
61. Chintharlapalli S, Papineni S, Lee SO, Lei P, Jin UH, Sherman SI, Santarpia L, Safe S. Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins. Mol Carcinog 50(9):655-67, 2011. e-Pub 2011. PMID: 21268135.
62. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29(19):2660-6, 2011. e-Pub 2011. PMID: 21606412.
63. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Waguespack SG, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R, Busaidy NL. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 96(4):997-1005, 2011. e-Pub 2011. PMID: 21289252.
64. Moreno MA, Agarwal G, de Luna R, Siegel ER, Sherman SI, Edeiken-Monroe BS, Clayman GL. Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancer. Arch Otolaryngol Head Neck Surg 137(2):157-62, 2011. PMID: 21339402.
65. Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JW, Reike G, Chung J, Kalmus J, Kappeler C, Schlumberger M. Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)–refractory, differentiated thyroid cancer. BMC Cancer 11(1):349, 2011. e-Pub 2011. PMID: 21834960.
66. Bass MB, Sherman SI, Schlumberger MJ, Davis MT, Kivman L, Khoo HM, Notari KH, Peach M, Hei YJ, Patterson SD. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 95(11):5018-27, 2010. e-Pub 2010. PMID: 20739388.
67. Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey JC, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ. Thyroid carcinoma. J Natl Compr Canc Netw 8(11):1228-74, 2010. PMID: 21081783.
68. Bhatia A, Rao A, Ang KK, Garden AS, Morrison WH, Rosenthal DI, Evans DB, Clayman G, Sherman SI, Schwartz DL. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head Neck 32(7):829-36, 2010. PMID: 19885924.
69. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 95(6):2588-95, 2010. PMID: 20392874.
70. Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer 116(12):2974-83, 2010. PMID: 20564403.
71. Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, National Comprehensive Cancer Network. Medullary carcinoma. J Natl Compr Canc Netw 8(5):512-30, 2010. PMID: 20495082.
72. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes; evaluation of the risks and benefits. Diabetes Care 33(2):428-433, 2010. PMID: 20103558.
73. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167-214, 2009. PMID: 19860577.
74. Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 15(22):7061-8, 2009. e-Pub 2009. PMID: 19903778.
75. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R. Phase I clinical trials in 56 patients with thyroid cancer: The M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab 94(11):4423-32, 2009. e-Pub 2009. PMID: 19820016.
76. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants either after recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 94(11):4171-9, 2009. PMID: 19850694.
77. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Recurrence after treatment of micropapillary thyroid cancer. Thyroid 19(10):1043-1048, 2009. PMID: 19772419.
78. Clayman GL, Shellenberger TD, Ginsberg LE, Edeiken BS, El-Naggar AK, Sellin RV, Waguespack SG, Roberts DB, Mishra A, Sherman SI. Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck 31(9):1152-63, 2009. e-Pub 2009. PMID: 19360746.
79. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27(23):3794-801, 2009. e-Pub 2009. PMID: 19564535.
80. Smith GL, Smith BD, Garden AS, Rosenthal DI, Sherman SI, Morrison WH, Schwartz DL, Weber RS, Buchholz TA. Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based study. Head Neck 31(8):1031-8, 2009. PMID: 19360741.
81. Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Evans DB, Clayman G, Sherman SI, Garden AS. Post-operative external beam radiotherapy for differentiated thyroid cancer - Outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys 74(4):1083-91, 2009. e-Pub 2008. PMID: 19095376.
82. Santarpia L, Sherman SI, Marabotti A, Clayman GL, El-Naggar AK. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum Pathol 40(6):827-33, 2009. e-Pub 2009. PMID: 19200582.
83. Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: USA case-control study. Hepatology 49(5):1563-70, 2009. PMID: 19399911.
84. Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 94(4):1310-6, 2009. e-Pub 2009. PMID: 19158200.
85. Waguespack SG, Sherman SI, Williams MD, Clayman GL, Herzog CE. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid 19(4):407-12, 2009. PMID: 19355831.
86. Santarpia L, Gagel RF, Sherman SI, Sarlis NJ, Evans DB, Hoff AO. Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer. Head Neck 31(3):419-23, 2009. PMID: 18798312.
87. Gning I, Trask PC, Mendoza TR, Harle MT, Gutierrez KA, Kitaka SA, Sherman SI, Cleeland CS. Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory (MDASI THY). Oncology 76(1):59-68, 2009. e-Pub 2008. PMID: 19052478.
88. Santarpia L, El-Naggar AK, Sherman SI, Hymes SR, Gagel RF, Shaw S, Sarlis NJ. Four patients with cutaneous metastases from medullary thyroid cancer. Thyroid 18(8):901-5, 2008. PMID: 18651821.
89. Schwartz DL, Rana V, Shaw S, Yazbeck C, Ang KK, Morrison WH, Rosenthal DI, Hoff A, Evans DB, Clayman GL, Garden AS, Sherman SI. Postoperative radiotherapy for advanced medullary thyroid cancer-Local disease control in the modern era. Head Neck 30(7):883-888, 2008. e-Pub 2008. PMID: 18213725.
90. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ, Schlumberger MJ. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359(1):31-42, 2008. PMID: 18596272.
91. Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL, El-Naggar AK. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol 39(1):15-20, 2008. e-Pub 2007. PMID: 17949783.
92. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/AKT and RAS/RAF-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93(1):278-84, 2008. e-Pub 2007. PMID: 17989125.
93. Santarpia L, Sarlis NJ, Santarpia M, Sherman SI, Trimarchi F, Benvenga S. Mosaicism in von Hippel-Lindau disease: an event important to recognize. J Cell Mol Med 11(6):1408-15, 2007. PMID: 18205710.
94. Sherman SI, Angelos P, Ball DW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA Jr, Ridge JA, Shah JP, Sisson JC, Tuttle RM, Urist MM; National Comprehensive Cancer Network Thyroid Carcinoma Panel.. Thyroid carcinoma. J Natl Compr Canc Netw 5(6):568-621, 2007. PMID: 17623612.
95. Sherman SI. Practice point commentary: Can serum thyroglobulin levels predict patient outcome after treatment of differentiated thyroid carcinoma?. Nat Clin Pract Endocrinol Metab 3(7):510-511, 2007. e-Pub 2007. PMID: 17519916.
96. Golden WM, Weber KB, Hernandez TL, Sherman SI, Woodmansee WW, Haugen BR. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J Clin Endocrinol Metab 92(1):124-30, 2007. PMID: 17062760.
97. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN, Tessler FN. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Ultrasound Q 22(3):231-8; discussion 239-40, 2006. PMID: 17146329.
98. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16(12):1229-42, 2006. PMID: 17199433.
99. Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy N, Klein MJ, Sherman SI, Shah MH. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 91(6):2201-2204, 2006. e-Pub 2006. PMID: 16522694.
100. Ghori F, Polder KD, Pinter-Brown LC, Hoff AO, Gagel RF, Sherman SI, Duvic M. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab 91(6):2205-8, 2006. PMID: 16595600.
101. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47(4):648-54, 2006. PMID: 16595499.
102. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized controlled study. J Clin Endocrinol Metab 91(3):926-932, 2006. e-Pub 2005. PMID: 16384850.
103. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 91(3):878-84, 2006. e-Pub 2006. PMID: 16394083.
104. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM, American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16(2):109-42, 2006. PMID: 16420177.
105. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN, Tessler FN. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 237(3):794-800, 2005. PMID: 16304103.
106. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15(6):531-44, 2005. PMID: 16029119.
107. Sherman SI, Angelos P, Ball DW, Beenken SW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Jr, Ridge JA, Robbins R, Shah JP, Sisson JC, Thompson NW. Thyroid carcinoma. J Natl Compr Canc Netw 3(3):404-57, 2005. PMID: 16002006.
108. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 10(24):8594-602, 2004. PMID: 15623643.
109. Kouvaraki MA, Lee JE, Shapiro SE, Sherman SI, Evans DB. Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery 136(6):1183-91, 2004. PMID: 15657574.
110. Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R. Parathyroid carcinoma: a 22-year experience. Head Neck 26(8):716-26, 2004. PMID: 15287039.
111. Yip L, Lee JE, Shapiro SE, Waguespack SG, Sherman SI, Hoff AO, Gagel RF, Arens JF, Evans DB. Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198(4):525-34; discussion 534-5, 2004. PMID: 15051000.
112. Sclabas GM, Staerkel GA, Shapiro SE, Fornage BD, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg 186(6):702-9; discussion 709-10, 2003. PMID: 14672783.
113. Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 134(6):890-9; discussion 899-901, 2003. PMID: 14668720.
114. Pederson LC, Shapiro SE, Fritsche HA, Delpassand ES, Gagel RF, Sherman SI, Vassilopoulou-Sellin R, Evans DB, Lee JE. Potential role for intraoperative gamma probe identification of normal parathyroid glands. Am J Surg 186(6):711-7, 2003. PMID: 14672784.
115. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monroe BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134(6):946-54; discussion 954-5, 2003. PMID: 14668727.
116. Shepler TR, Sherman SI, Faustina MM, Busaidy NL, Ahmadi MA, Esmaeli B. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma. Ophthal Plast Reconstr Surg 19(6):479-81, 2003. PMID: 14625496.
117. Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hänscheid H, Reiners C. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 30(10):1371-7, 2003. e-Pub 2003. PMID: 12856155.
118. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88(4):1433-41, 2003. PMID: 12679418.
119. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138(4):409-16; discussion 416, 2003. PMID: 12686527.
120. Sherman SI. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clin Lymphoma 3(4):249-52, 2003. PMID: 12672276.
121. Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG, Sherman SI. Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer 97(5):1186-94, 2003. PMID: 12599224.
122. Royal RE, Delpassand ES, Shapiro SE, Fritsche HA, Vassilopoulou-Sellin R, Sherman SI, Gagel RF, Evans DB, Lee JE. Improving the yield of preoperative parathyroid localization: technetium Tc 99m-sestamibi imaging after thyroid suppression. Surgery 132(6):968-74; discussion 974-5, 2002. PMID: 12490843.
123. Ghori FY, Gutterman-Litofsky DR, Jamal A, Yeung SC, Arem R, Sherman SI. Socioeconomic factors and the presentation, management, and outcome of patients with differentiated thyroid carcinoma. Thyroid 12(11):1009-16, 2002. PMID: 12490079.
124. Kouvaraki MA, Lee JE, Shapiro SE, Gagel RF, Sherman SI, Sellin RV, Cote GJ, Evans DB. Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg 137(6):641-7, 2002. PMID: 12049533.
125. Wartofsky L, Sherman SI (group member). Management of low risk well differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. the rhTSH-Stimulated Thyroglobulin Study Group. Thyroid 12(7):583-590, 2002. PMID: 12193302.
126. Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB. Optimal treatment strategy in patients with papillary thyroid cancer: A decision analysis. Surgery 130(6):921-30, 2001. PMID: 11742318.
127. McCutcheon IE, Kitagawa RH, Sherman SI, Bruner JM. Adenocarcinoma of the salivary gland metastatic to the pituitary gland: case report. Neurosurgery 48(5):1161-5; discussion 1165-6, 2001. PMID: 11334286.
128. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84(11):3877-85, 1999. PMID: 10566623.
129. Fleming JB, Lee JE, Bouvet M, Schultz PN, Sherman SI, Sellin RV, Friend KE, Burgess MA, Cote GJ, Gagel RF, Evans DB. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 230(5):697-707, 1999. PMID: 10561095.
130. Sturgis CD, Caraway NP, Johnston DA, Sherman SI, Kidd L, Katz RL. Image analysis of papillary thyroid carcinoma fine-needle aspirates: significant association between aneuploidy and death from disease. Cancer 87(3):155-60, 1999. PMID: 10385447.
131. Arem R, Padayatty SJ, Saliby AH, Sherman SI. Thyroid microcarcinoma: prevalence, prognosis, and management. Endocr Pract 5(3):148-56, 1999. PMID: 15251688.
132. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 340(14):1075-9, 1999. PMID: 10194237.
133. Lee JE, Evans DB, Hickey RC, Sherman SI, Gagel RF, Abbruzzese MC, Abbruzzese JL. Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas. Surgery 124(6):1115-22, 1998. PMID: 9854592.
134. Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 83(12):4195-203, 1998. PMID: 9851751.
135. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, Nishiyama R, Ross D, Sherman S, Maxon HR. Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma. Ann Intern Med 129(8):622-7, 1998. PMID: 9786809.
136. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR. Prospective multicenter study of thyroid carcinoma treatment: Initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83(5):1012-21, 1998. PMID: 9731906.
137. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8(9):737-44, 1998. PMID: 9777742.
138. Chiu AC, Sherman SI. Effects of pharmacological fiber supplements on levothyroxine absorption. Thyroid 8(8):667-71, 1998. PMID: 9737361.
139. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 82(11):3637-42, 1997. PMID: 9360519.
140. Sherman SI, Ringel MD, Smith MJ, Kopelen HA, Zoghbi WA, Ladenson PW. Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine. J Clin Endocrinol Metab 82(7):2153-8, 1997. PMID: 9215287.
141. Sherman SI, Simonson L, Ladenson PW. Clinical and socioeconomic predispositions to complicated thyrotoxicosis: a predictable and preventable syndrome?. Am J Med 101(2):192-8, 1996. PMID: 8757360.
142. Sherman SI, Malecha SE. Absorption and malabsorption of levothyroxine sodium. Am J Ther 2(10):814-818, 1995. PMID: 11854792.
143. Sherman SI, Tielens ET, Ladenson PW. Sucralfate causes malabsorption of L-thyroxine. Am J Med 96(6):531-5, 1994. PMID: 8017451.
144. Sherman SI, Tielens ET, Sostre S, Wharam MD, Ladenson PW. Clinical utility of post treatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 78(3):629-34, 1994. PMID: 8126134.
145. Tielens ET, Sherman SI, Hruban RH, Ladenson PW. Follicular variant of papillary thyroid carcinoma. A clinicopathologic study. Cancer 73(2):424-31, 1994. PMID: 8293410.
146. Sherman SI, Ladenson PW. Organ-specific effects of tiratricol: a thyroid hormone analogue with hepatic, not pituitary, superagonist effects. J Clin Endocrinol Metab 75(3):901-5, 1992. PMID: 1517383.
147. Ladenson PW, Sherman SI, Baughman KL, Ray PE, Feldman AM. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci U S A 89(12):5251-5, 1992. PMID: 1376915.
148. Sherman SI, Ladenson PW. Octreotide therapy of growth hormone excess in the McCune-Albright syndrome. J Endocrinol Invest 15(3):185-90, 1992. PMID: 1624678.
149. Sherman SI, Ladenson PW. Percutaneous transluminal coronary angioplasty in hypothyroidism. Am J Med 90(3):367-70, 1991. PMID: 2003519.

Invited Articles

1. Hofmann MC, Kunnimalaiyaan M, Wang JR, Busaidy NL, Sherman SI, Lai SY, Zafereo M, Cabanillas ME. Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers. Endocr Relat Cancer 29(11):R173-R190, 2022. e-Pub 2022. PMID: 35975971.
2. Weitzman SP, Sherman SI. Novel Drug Treatments of Progressive Radioiodine Refractory Differentiated Thyroid Cancer. Endocrinol Metab Clin North Am 48(1):253-268, 2019. e-Pub 2018. PMID: 30717907.
3. Sherman SI. Evolution of Targeted Therapies for Thyroid Carcinoma. Transactions of the American Clinical and Climatological Association 130:255-265, 2019. PMID: 31516190.
4. Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, Mandel SJ, Morris JC, Nassar A, Pacini F, Schlumberger M, Schuff K, Sherman SI, Somerset H, Sosa JA, Steward DL, Wartofsky L, Williams MD. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid 27(4):481-483, 2017. e-Pub 2017. PMID: 28114862.
5. Dralle H, Machens A, Basa J, Fatourechi V, Franceschi S, Hay ID, Nikiforov YE, Pacini F, Pasieka JL, Sherman SI. Follicular Cell-derived Thyroid Cancer. Nat Rev Dis Primers 1(Article number 15077):15077, 2015. e-Pub 2015. PMID: 27188261.
6. Czerwonka L, Freeman J, McIver B, Randolph GW, Shah JP, Shaha AR, Sherman SI, Tuttle RM, Witterick IJ. Summary of proceedings of the second World Congress on Thyroid Cancer. Head and Neck 36(7):917-920, 2014. e-Pub 2014. PMID: 24677329.
7. Haddad R, Sherman SI, Shah JP, Wirth LJ. New frontiers and treatment paradigms for thyroid carcinoma. Clinical Advances in Hematology & Oncology 12(7):3-22, 2014. PMID: 25768715.
8. Sherman SI. Overview of radioactive iodine-resistant differentiated thyroid cancer. Clinical Advances in Hematology and Oncology 12(7):3-5, 2014.
9. Sherman SI. Molecular mechanisms in thyroid cancer biology. Clinical Advances in Hematology and Oncology 12(7):10-13, 2014.
10. Sherman SI. Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer. Oral Oncol 49(7):707-10, 2013. e-Pub 2013. PMID: 23582411.
11. Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev 34(3):439-455, 2013. e-Pub 2013. PMID: 23575762.
12. Witt RL, Ferris RL, Pribitkin EA, Sherman SI, Steward DL, Nikiforov YE. Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope 123(4):1059-64, 2013. e-Pub 2013. PMID: 23404751.
13. Sherman SI. The role of recombinant human thyrotropin for diagnostic monitoring of patients with differentiated thyroid cancer. Endocr Pract 19(1):157-61, 2013. PMID: 23435044.
14. Cabanillas ME, Sherman SI. Applying new clinicopathologic characteristics to prognostication in advanced thyroid carcinoma. Endocr Relat Cancer 19(2):C19-22, 2012. e-Pub 2012. PMID: 22241721.
15. Schlumberger M, Sherman SI. Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol 166(1):5-11, 2012. e-Pub 2011. PMID: 21890651.
16. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies-review of the scientific evidence. J Clin Endocrinol Metab 96(7):2027-31, 2011. PMID: 21734003.
17. Sherman SI. Targeted therapies for thyroid tumors. Mod Pathol 24 Suppl 2:S44-52, 2011. PMID: 21455200.
18. Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharmacol 80(5):592-601, 2010. e-Pub 2010. PMID: 20471374.
19. Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 22(6):464-8, 2010. e-Pub 2010. PMID: 20452757.
20. Sherman SI. Chemotherapy for differentiated thyroid cancer. UpToDate 18(2), 2010.
21. Sherman SI. Chemotherapy and immunotherapy for medullary thyroid carcinoma. UpToDate 18(2), 2010.
22. Schlumberger M, Sherman SI. Clinical trials for progressive differentiated thyroid cancer: Patient selection, study design, and recent advances. Thyroid 19(12):1393-1400, 2009. PMID: 20001721.
23. Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 23(6):713-722, 2009. PMID: 19942148.
24. Sherman SI. Molecularly targeted therapies for thyroid cancers. Endocr Pract 15(6):1-27, 2009. e-Pub 2009. PMID: 19546052.
25. Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94(5):1493-9, 2009. e-Pub 2009. PMID: 19258410.
26. Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am 37(2):511-24, xi, 2008. PMID: 18502340.
27. Sherman SI. New approaches to therapy of thyroid malignancies. Clin Adv Hematol Oncol 5(7):539-541, 2007. PMID: 17679927.
28. Sherman SI. Cancer disparities and thyroid carcinoma. Curr Opin Endocrinol Metab 13:451-4, 2006.
29. Sherman SI. Review of undifferentiated thyroglobulin-positive thyroid cancer 45 years after treatment for papillary primary. Clin Adv Hemat Oncol 1(4):243, 2005.
30. Sherman SI. Commentary on: Angelos P. Current approaches to the treatment of well-differentiated thyroid cancer. Oncology (Huntington) 16(3):309-315, discussion 315, 318, 323-4,, 2002.
31. Tyler DS, Shaha AR, Udelsman RA, Sherman SI, Thompson NW, Moley JF, Evans DB. Thyroid cancer: 1999 update. Ann Surg Oncol 7(5):376-98, 2000. PMID: 10864346.
32. Sherman SI. The management of metastatic differentiated thyroid carcinoma. Rev Endocr Metab Disord 1(3)(3):165-71, 2000. PMID: 11705002.
33. Sherman, SI, Gillenwater AM, Goepfert H. Advances in the management of cancer of the thyroid gland. Advances in Otolaryngology B Head and Neck Surgery 14:75-106, 2000.
34. Sherman SI. Clinicopathologic and prognostic staging for thyroid carcinomas. Thyroid Today 23(3):1-9, 2000.
35. Sherman SI. Papillary thyroid carcinoma. UpToDate in Medicine [CD-ROM] 8(2, 2000.
36. Sherman SI. Thyroid carcinoma. Lancet 361(9356):501-11, 2000. PMID: 12583960.
37. Sherman SI. Adjuvant therapy and long-term management of differentiated thyroid carcinoma. Semin Surg Oncol 16(1):30-3, 1999. PMID: 9890737.
38. Sherman SI. Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma. Semin Surg Oncol 16(1):12-5, 1999. PMID: 9890734.
39. Sherman SI. Serum thyroglobulin in the management of differentiated thyroid carcinoma. UpToDate in Medicine [CD-ROM] 6(3), 1998.
40. Sherman SI. Anaplastic thyroid carcinoma. UpToDate in Medicine [CD-ROM] 5(2), 1997.
41. Sherman SI. Clinicopathologic staging of differentiated thyroid carcinoma. UpToDate in Medicine [CD-ROM] 5(1), 1997.
42. Sherman SI. Management of differentiated thyroid carcinoma. An overview. UpToDate in Medicine [CD-ROM] 5(1), 1997.
43. Sherman SI. Medullary thyroid carcinoma: Clinical presentation, genetics, and prognostic staging. UpToDate in Medicine [CD-ROM] 5(2), 1997.
44. Sherman SI. Medullary thyroid carcinoma: Treatment. . UpToDate in Medicine [CD-ROM] 5(2), 1997.
45. Sherman SI. Radioiodine treatment of differentiated thyroid cancer. UpToDate in Medicine [CD-ROM] 4(2), 1996.
46. Sherman SI. Surgery for differentiated thyroid carcinoma. UpToDate in Medicine [CD-ROM] 4(3), 1996.
47. Evans, DB,Sherman SI. Long-term follow-up and management of papillary adenocarcinoma of the thyroid. Collected Letters in Surgery 18(9):5-7, 1995.

Manuals, Teaching Aids, Other Teaching Publications

1. Sherman SI, Haddad RI. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC. Medscape Education: New York City, 2015.
2. Sherman SI. Your Care Path: Thyroidectomy. Prepared for patients entered in institutional critical pathways for thyroid surgery, 2000.

Editorials

1. Sturgis EM, Sherman SI. Should papillary thyroid carcinoma be observed?: a word of caution. Arch Otolaryngol Head Neck Surg 136(5):444-6, 2010. PMID: 20479372.
2. Sherman SI, Fagin J. Why thyroid cancer?. Thyroid 15(4):303-04, 2005.
3. Sherman SI. Optimizing the outcomes of adjuvant radioiodine therapy in differentiated thyroid carcinoma. J Clin Endocrinol Metab 87(9):4059-4062, 2002. PMID: 12213844.
4. Sherman SI. Staging of thyroid carcinoma--reply. Cancer 83(5):848-50, 1998. PMID: 9731885.
5. Sherman SI. The risks of thyroidectomy: words of caution for referring physicians. J Gen Intern Med 13(1):60-1, 1998. PMID: 9462498.

Abstracts

1. Wirth,LJ, Brose,MS, Sherman,EJ, Misir,S, Xie,S, Almonte,A, Ye,W, Licitra,L, Schlumberger,M, Sherman,SI, Cabanillas,M. An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib (LEN) for the Treatment of Anaplastic Thyroid Cancer (ATC). Journal of the Endocrine Society 4(Supplement 1):MON-521, 2020.
2. Fazeli,S, Dadu,R, Waguespack,SG, Sherman,SI, Busaidy,NL, Hu,MI, Jimenez,C, Habra,MA, Williams,M, Altameemi,L, Poropatich,K, Routbort,MJ, Luthra,R, Patel,KP, Cabanillas,M. TRK-Fusion Thyroid Cancer: A Clinical Overview in a Large Population at a Single Cancer Center. Journal of the Endocrine Society 4(Supplement 1):MON-491, 2020.

Book Chapters

1. Sherman SI. RAI-Refractory Differentiated Thyroid Cancer with Multiple Organ Progressive Disease; RAI-Refractory Differentiated Thyroid Cancer and Lung Lesions Causing Bleeding; Differentiated Thyroid Cancer and Brain Metastases; RAI-Refractory, Advanced Differentiated Thyroid Cancer Receiving Tyrosine Kinase Inhibitor Treatment: Checking for Drug:Drug Interactions. In: Thyroid Cancer: A Case Based Approach. 2nd. Springer: Switzerland, 261-68; 269-274; 297-302; 303-310, 2021.
2. Filetti, S, Tuttle, RM, Sherman, SI. Medical management of differentiated epithelial cell thyroid cancer. In: Werner & Ingbar's The Thyroid. 11. Wolters Kluwer Health, 751-775, 2020.
3. Filetti S, Sherman SI. New (Medical) Treatment for Thyroid Carcinoma. In: Thyroid Diseases: Pathogenesis, Diagnosis, and Treatment. Springer: Switzerland, 645-670, 2018.
4. Sherman SI, Cabanillas ME, Lai SY. Neoplasms of the Thyroid. In: Holland - Frei Cancer Medicine. 9th. Wiley: Hoboken, NJ, 959-966, 2017.
5. Sherman SI. RAI-Refractory Differentiated Thyroid Cancer with Multiple Organ Progressive Disease; RAI-Refractory Differentiated Thyroid Cancer and Lung Lesions Causing Bleeding; Differentiated Thyroid Cancer and Brain Metastases; RAI-Refractory, Advanced Differentiated Thyroid Cancer Receiving Tyrosine Kinase Inhibitor Treatment: Checking for Drug:Drug Interactions. In: Thyroid Cancer. Springer, 279-86; 287-92; 307-14; 315-20, 2016.
6. Sherman SI. Thyroid Cancer. In: The Molecular Basis of Cancer: 4th Edition. 4th. Elsevier Press: Philadelphia, 601-608, 2014.
7. Filetti S, Tuttle RM, Sherman SI. Medical Management of Differentiated Epithelial Thyroid Cancer. In: Werner & Ingbar's The Thyroid. 10th. Lippincott Williams & Wilkins: Philadelphia, 725-743, 2013.
8. Sherman, SI, Perrier N, Clayman CL. 60 Years of Survival Outcomes at the University of Texas MD Anderson Cancer Center. In: Thyroid Cancer. Springer New York: New York, 295-310, 2013.
9. Sherman SI. Biologically Targeted Therapies for Thyroid Cancers. In: Thyroid Cancer From Emergent Biotechnologies to Clinical Practice Guidelines. CRC Press Taylor & Francis Group: Florida, 329-349, 2011.
10. Hu M, Sherman SI. Endocrine Complications of Head and Neck Surgery. In: Complications in Head and Neck Surgery. 2nd Edition. Mosby: Philadelphia, 85-103, 2009.
11. Sherman SI, Talbert RL. Thyroid Disorders. In: Pharmacotherapy: A Pathophysiologic Approach. 7th Edition. McGraw Hill: New York, 1243-1264, 2008.
12. Sherman SI. The Laboratory Approach to Thyroid Disorders. In: Medical Management of Thyroid Disease. 2nd Edition. Informa Healthcare USA: New York, 1-38, 2008.
13. Sherman SI, Gillenwater AM. Neoplasia of the Thyroid. In: Cancer Medicine. 7th Edition. B.C. Decker: Hamilton, Ontario, 1093-1102, 2006.
14. Sherman SI. Anaplastic Carcinoma: Clinical Aspects; Anaplastic Carcinoma: Prognosis; Thyroid Lymphoma. In: Thyroid Cancer: A Comprehensive Guide to Clinical Management. 2nd Edition. Humana Press: Totowa, NJ, 615-20, 629-32, 647-52, 2006.
15. Sherman SI. Directions for Future Studies and Clinical Trials. In: Practical Management of Thyroid Cancer: A Multidisciplinary Approach. Springer, 429-34, 2005.
16. Sherman SI, Gagel RF. Disorders Affecting Multiple Endocrine Systems. In: Harrison’s Principles of Internal Medicine 16th edition. McGraw-Hill, 2231-2238, 2004.
17. Gillenwater AM, Sherman SI, El-Naggar AK, Helmuth G. Hurthle Cell Carcinoma of the Thyroid. In: Surgery of the Thyroid and Parathyroid Glands. W.B. Saunders, 227-231, 2003.
18. Sherman SI, Gillenwater AM. Neoplasia of the Thyroid. In: Cancer Medicine 6th edition. Decker, 2003.
19. Sherman SI, Lopez-Penabad L. The Use of Recombinant Human Thyrotropin in the Management of Thyroid Carcinoma and other Thyroid Disorders. In: Endocrine Replacement Therapy in Clinical Practice, 113-128, 2003.
20. Hoff AO, Sherman SI, Gagel RF. Radioiodine Treatment in Differentiated Thyroid Malignancy. In: Endocrine Surgery of the Head and Neck. Delmar Learning, 201-208, 2002.
21. Sherman SI, Gagel RF. Disorders Affecting Multiple Endocrine Systems. In: Harrison’s Principles of Internal Medicine 15th edition. McGraw-Hill, 2184-2192, 2001.
22. Sherman SI. The Laboratory Approach to Thyroid Disorders. In: Medical Management of Thyroid Disease. Marcel Decker, 2001.
23. Deftos L, Sherman SI, Gagel RF. Multiglandular Endocrine Disorders. In: Endocrinology and Metabolism. 4th edition. McGraw-Hill, 1355-1382, 2001.
24. Sherman SI, Gillenwater AM. Neoplasia of the Thyroid. In: Cancer Medicine 5th edition. Decker, 2000.
25. Sherman SI. Anaplastic Carcinoma: Clinical Aspects; Anaplastic Carcinoma: Prognosis; Thyroid Lymphoma. In: Thyroid Cancer, Clinical Management. Humana Press, 319-326, 345-350, 351-358, 1999.
26. Chiu, AC, Sherman SI. Clinical Manifestations and Differential Diagnosis of Hypothyroidism. In: Thyroid Disease: Endocrinology, Surgery, Nuclear Medicine and Radiotherapy. 2nd edition. Lippincott-Raven, 379-392, 1997.
27. Sherman SI, Gagel RF. Disorders Affecting Multiple Endocrine Systems. In: Harrison’s Principles of Internal Medicine 14th edition. McGraw-Hill, 1997.
28. Sherman, SI, Ladenson PW. Thyroid Gland. In: Laboratory Medicine: The Selection and Interpretation of Clinical Laboratory Studies. Williams & Wilkins, 629-645, 1994.
29. Sherman, SI, Ladenson PW. Endocrine Complications of Head and Neck Surgery. In: Complications in Head and Neck Surgery. Mosby-Year Book, Inc, 83-93, 1993.

Letters to the Editor

1. Yin N, Sherman SI, Pak Y, Litofsky DR, Gianoukakis AG. Response to Rosário and Souza Côrtes re: "The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence". Thyroid 30: 1689-1687, 2020.
2. Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI, from the National Thyroid Cancer Treatment Cooperative Study Group (NTCTCSG), Houston, Texas. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid 20: 1423-4, 2010.
3. Sherman SI, Ladenson PW. Subacute thyroiditis causing thyroid storm. Thyroid 17: 283, 2007.
4. Lee JE, Evans DB, Sherman SI, Gagel RF. Evaluation of the incidental adrenal mass. Am J Med 103: 249-50, 1997.